Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. GlaxoSmithKline (GSK) downgraded to Neutral from Buy at BofA/Merrill with analyst Graham Parry citing increasing headwinds including 2018 margin pressure and consensus reductions from Advair generic erosion, HIV franchise risk from competition, and dividend uncertainty. 2. Global Eagle (ENT) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying Ernst & Young declining to stand for re-appointment increases the chances of an annual filing delay and a potential subsequent delisting by Nasdaq. The analyst cut his price target for the shares to $2 from $3. 3. trivago (TRVG) downgraded to Underperform from Neutral at BofA/Merrill and to Neutral from Buy at Guggenheim. 4. Lear (LEA) downgraded to Neutral from Buy at Guggenheim. 5. L Brands (LB) downgraded to Neutral from Buy at Buckingham with analyst Kelly Halsor saying she believes L Brands' margin recovery is facing headwinds in both brands resulting in incremental pricing investments and promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
click here.